澳大利亚发育障碍诊所人群的呼吸药物使用情况：给医护人员的启示

Respiratory medication use in an Australian developmental disability clinic population: messages for health care professionals.

作者信息

Davis Sharon R, Durvasula Seeta, Merhi Diana, Young Paul M, Traini Daniela, Bosnic-Anticevich Sinthia Z

机构信息

Woolcock Institute of Medical Research and Discipline of Pharmacology, Sydney Medical School, The University of Sydney, PO Box M77, Missenden Road, NSW 2050, Australia.

Centre for Disability Studies, Sydney Medical School, University of Sydney, Level 1, Medical Foundation Building - K25, 92-94 Parramatta Road, Camperdown, NSW 2050, Australia.

出版信息

Aust J Prim Health. 2014;20(3):278-84. doi: 10.1071/PY12153.

DOI:10.1071/PY12153

PMID:23693140

Abstract

Australian data suggest up to 15% of people with intellectual disability (ID) have asthma. The inhaled route of administration is optimal for the management of obstructive airways diseases; however, correct inhaler use requires dexterity and particular breathing patterns and potentially represents a problem in this population due to physical and cognitive deficits. Understanding the nature and extent of inhaler use in persons with ID is important, as correct inhaler technique is imperative for optimal clinical outcomes; however, currently no evidence base exists to inform health professionals. This study describes respiratory medication use, reported prevalence of asthma, and asthma management practices undertaken in a clinic sample of Australian adults with ID. Results showed a prevalence of retrospectively reported asthma of 6%, with 86% of asthma patients prescribed inhaled medication. A review of patient records also indicated omission of some recommended asthma management strategies.

摘要

澳大利亚的数据表明，高达15%的智力残疾者患有哮喘。吸入给药途径是治疗阻塞性气道疾病的最佳方式；然而，正确使用吸入器需要灵活性和特定的呼吸模式，由于身体和认知缺陷，这对该人群来说可能是个问题。了解智力残疾者使用吸入器的性质和程度很重要，因为正确的吸入器技术对于获得最佳临床效果至关重要；然而，目前尚无证据基础为卫生专业人员提供参考。本研究描述了澳大利亚成年智力残疾者临床样本中使用的呼吸药物、报告的哮喘患病率以及哮喘管理措施。结果显示，回顾性报告的哮喘患病率为6%，86%的哮喘患者使用吸入药物。对患者记录的审查还表明，一些推荐的哮喘管理策略被遗漏。